Larry G. Edwards
Chief Executive Officer presso Aicuris Anti-Infective Cures AG
Profilo
Larry G.
Edwards is a businessperson who has been the head of 5 different companies.
Currently, he is Chief Executive Officer of Aicuris Anti-Infective Cures AG.
He is also on the board of La Jolla Pharmaceutical II BV, UTILITY therapeutics Ltd.
and Clarametyx Biosciences, Inc.
In the past he occupied the position of President & Chief Executive Officer for Tetraphase Pharmaceuticals Ireland Ltd., Director-Global Marketing at Merck & Co., Inc., Senior Director-Marketing at Cubist Pharmaceuticals LLC, President & Chief Executive Officer of La Jolla Pharmaceutical Co., President, Chief Executive Officer & Director at Tetraphase Pharmaceuticals, Inc. and President & Chief Executive Officer at La Jolla Pharma LLC.
Mr. Edwards received an undergraduate degree from The Ohio University and an MBA from Boston University.
Posizioni attive di Larry G. Edwards
Società | Posizione | Inizio |
---|---|---|
Clarametyx Biosciences, Inc.
Clarametyx Biosciences, Inc. BiotechnologyHealth Technology Clarametyx Biosciences, Inc. operates as a biotechnology company. It develops a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections. The company was founded by Michael Triplett, Peter G. Kleinhenz, Juliana Woda, and Charles McOsker and is headquartered in Columbus, OH. | Director/Board Member | - |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Director/Board Member | 01/03/2021 |
La Jolla Pharmaceutical II BV
La Jolla Pharmaceutical II BV Medical/Nursing ServicesHealth Services Part of Innoviva, Inc., La Jolla Pharmaceutical II BV provides healthcare services. The private company is based in Amsterdam, Netherlands. | Director/Board Member | - |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The private company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Chief Executive Officer | 01/04/2023 |
Precedenti posizioni note di Larry G. Edwards
Società | Posizione | Fine |
---|---|---|
LA JOLLA PHARMACEUTICAL COMPANY | Chief Executive Officer | 01/04/2023 |
La Jolla Pharma LLC
La Jolla Pharma LLC Pharmaceuticals: MajorHealth Technology Part of Innoviva, Inc., La Jolla Pharma LLC is a pharmaceutical company that manufactures pharmaceutical products. The private company is based in Dover, DE. | Chief Executive Officer | 01/04/2023 |
TETRAPHASE PHARMACEUTICALS, INC. | Chief Executive Officer | 28/07/2020 |
CUBIST PHARMACEUTICALS INC | Sales & Marketing | 01/07/2015 |
MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2010 |
Formazione di Larry G. Edwards
Boston University | Masters Business Admin |
The Ohio University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
MERCK & CO., INC. | Health Technology |
Aziende private | 9 |
---|---|
La Jolla Pharmaceutical Co.
La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Cubist Pharmaceuticals LLC
Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
La Jolla Pharmaceutical II BV
La Jolla Pharmaceutical II BV Medical/Nursing ServicesHealth Services Part of Innoviva, Inc., La Jolla Pharmaceutical II BV provides healthcare services. The private company is based in Amsterdam, Netherlands. | Health Services |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Health Technology |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The private company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Commercial Services |
La Jolla Pharma LLC
La Jolla Pharma LLC Pharmaceuticals: MajorHealth Technology Part of Innoviva, Inc., La Jolla Pharma LLC is a pharmaceutical company that manufactures pharmaceutical products. The private company is based in Dover, DE. | Health Technology |
Clarametyx Biosciences, Inc.
Clarametyx Biosciences, Inc. BiotechnologyHealth Technology Clarametyx Biosciences, Inc. operates as a biotechnology company. It develops a dynamic pipeline of immune-enabling therapies and vaccines for chronic and recurrent bacterial infections. The company was founded by Michael Triplett, Peter G. Kleinhenz, Juliana Woda, and Charles McOsker and is headquartered in Columbus, OH. | Health Technology |
Tetraphase Pharmaceuticals Ireland Ltd.
Tetraphase Pharmaceuticals Ireland Ltd. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals Ireland Ltd. is an Irish private company located in Dublin that manufactures basic pharmaceutical products. | Health Technology |